VIVES is a multi-sector fund that invests in projects with a positive societal impact
e-Peas stands for Electronic Portable Energy Autonomous Systems.
The company was founded in 2014 on the conviction that the trillions of connected IoT nodes that will be deployed in the next few...
Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models.
With the...
SmartNodes is a provider of innovative control modules for dynamic outdoor lighting: "Light where and when you want, at the right level".
Maximum energy savings are achieved without reducing the...
Gael Rouvroy, CEO intoPIX :
"VIVES fund has been a great partner in early and mature stages of intoPIX. They recognized the potential of the market and the technology with a primary recognition for...
Pierre-Antoine Mariage, co-CEO Botalys :
"VIVES trusted us at an early stage. In addition to their financial investment, they offer us a regular and wise coaching from their experts while respecting...
Vincent Mouret, Chairman of the board of Cissoid :
"As Chairman of the board of Cissoid, I’ve been working closely to VIVES for the last 10 years.
I have really appreciated VIVES involvement and...
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease
Four young patients were treated
VIVES Partners’ portfolio investment The Akkermansia Company (TAC) acquired by Danone
Acquisition of TAC’s gut microbiota product, with benefits for people at risk of cardiovascular disease